173 related articles for article (PubMed ID: 34583545)
1. [Radiation Oncology - Recent Status].
Studer G; Glanzmann C
Praxis (Bern 1994); 2021 Sep; 110(13):733-742. PubMed ID: 34583545
[TBL] [Abstract][Full Text] [Related]
2. [Radiotherapy for patients with early-stage glottic squamous cell carcinoma of the larynx: Interest of hypofractionation?].
Tonneau M; Matta R; Lals S; Mirabel X; Crop F; Lacornerie T; Pasquier D; Escande A; Liem X
Cancer Radiother; 2021 Dec; 25(8):801-810. PubMed ID: 33931299
[TBL] [Abstract][Full Text] [Related]
3. [Practice changing clinical trials in radiation oncology in 2022].
Antoni D; Claude L; Laprie A; Lévy A; Peignaux K; Rivera S; Schick U
Cancer Radiother; 2022 Oct; 26(6-7):823-833. PubMed ID: 36055908
[TBL] [Abstract][Full Text] [Related]
4. [Innovation in radiotherapy: A glance at 2018].
Vial N; Vallard A; Jmour O; Rehailia-Blanchard A; Ben Mrad M; Trone JC; Daguenet E; Guy JB; Magné N
Bull Cancer; 2019 Jan; 106(1):48-54. PubMed ID: 30616840
[TBL] [Abstract][Full Text] [Related]
5. [Ultra-hypofractionated radiotherapy for the treatment of localized prostate cancer: Results, limits and prospects].
Graff P; Crehange G
Cancer Radiother; 2021 Oct; 25(6-7):684-691. PubMed ID: 34274223
[TBL] [Abstract][Full Text] [Related]
6. Are We Choosing Wisely in Radiation Oncology Practice-Findings From an Australian Population-Based Study.
Ong WL; Foroudi F; Milne RL; Millar JL
Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1012-1016. PubMed ID: 30981834
[TBL] [Abstract][Full Text] [Related]
7. Hypofractionated stereotactic radiotherapy for challenging brain metastases using 36 Gy in six fractions.
Dumont Lecomte D; Lequesne J; Geffrelot J; Lesueur P; Barraux V; Loiseau C; Lacroix J; Leconte A; Émery É; Thariat J; Stefan D
Cancer Radiother; 2019 Dec; 23(8):860-866. PubMed ID: 31677901
[TBL] [Abstract][Full Text] [Related]
8. [Hypofractionated stereotactic body radiation therapy for adrenal metastases].
Dupic G; Biau J; Bellière-Calandry A; Lapeyre M
Cancer Radiother; 2017 Aug; 21(5):404-410. PubMed ID: 28684242
[TBL] [Abstract][Full Text] [Related]
9. [Delineation of organs at risk and dose constraints].
Noël G; Antoni D; Barillot I; Chauvet B
Cancer Radiother; 2016 Sep; 20 Suppl():S36-60. PubMed ID: 27516050
[TBL] [Abstract][Full Text] [Related]
10. [Moderate or extreme hypofractionation and localized prostate cancer: The times are changing].
Line Krhili S; Créhange G; Albert-Dufrois H; Guimas V; Minsat M; Supiot S
Cancer Radiother; 2019 Oct; 23(6-7):503-509. PubMed ID: 31471253
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness research in radiation oncology: stereotactic radiosurgery, hypofractionation, and brachytherapy.
Aneja S; Yu JB
Semin Radiat Oncol; 2014 Jan; 24(1):35-42. PubMed ID: 24314340
[TBL] [Abstract][Full Text] [Related]
12. [Hypofractionated radiotherapy in prostate cancer].
Supiot S; Créhange G; Latorzeff I; Pommier P; Paumier A; Rio E; Delaroche G; Guérif S; Catton C; Martin J; Lisbona A
Cancer Radiother; 2013 Oct; 17(5-6):349-54. PubMed ID: 23973460
[TBL] [Abstract][Full Text] [Related]
13. We've Got a Treatment, but What's the Disease? Or A Brief History of Hypofractionation and Its Relationship to Stereotactic Radiosurgery.
Rosenthal DI; Glatstein E
Oncologist; 1996; 1(1 & 2):1-7. PubMed ID: 10387962
[TBL] [Abstract][Full Text] [Related]
14. Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer.
Beckta JM; Nosrati JD; Yu JB
Urol Oncol; 2019 Sep; 37(9):619-627. PubMed ID: 30738746
[TBL] [Abstract][Full Text] [Related]
15. [Stereotactic body radiation therapy for spinal metastases].
Pasquier D; Martinage G; Mirabel X; Lacornerie T; Makhloufi S; Faivre JC; Thureau S; Lartigau É
Cancer Radiother; 2016 Oct; 20(6-7):500-7. PubMed ID: 27614511
[TBL] [Abstract][Full Text] [Related]
16. [Hypofractionated stereotactic radiotherapy of bone metastases].
Pichon B; Thillays F; Bourgier C; Mahé MA; Supiot S
Cancer Radiother; 2014; 18(4):342-9. PubMed ID: 24908177
[TBL] [Abstract][Full Text] [Related]
17. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Tsao MN; Mehta MP; Whelan TJ; Morris DE; Hayman JA; Flickinger JC; Mills M; Rogers CL; Souhami L
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):47-55. PubMed ID: 16111571
[TBL] [Abstract][Full Text] [Related]
18. Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL).
Murthy V; Mallick I; Gavarraju A; Sinha S; Krishnatry R; Telkhade T; Moses A; Kannan S; Prakash G; Pal M; Menon S; Popat P; Rangarajan V; Agarwal A; Kulkarni S; Bakshi G
BMJ Open; 2020 Feb; 10(2):e034623. PubMed ID: 32114475
[TBL] [Abstract][Full Text] [Related]
19. Managing patient flows in radiation oncology during the COVID-19 pandemic : Reworking existing treatment designs to prevent infections at a German hot spot area University Hospital.
Akuamoa-Boateng D; Wegen S; Ferdinandus J; Marksteder R; Baues C; Marnitz S
Strahlenther Onkol; 2020 Dec; 196(12):1080-1085. PubMed ID: 33123776
[TBL] [Abstract][Full Text] [Related]
20. How to integrate stereotactic body radiation therapy and hypofractionation in the management of stage III lung cancer in the age of immunotherapy.
Rico M; Flamarique Andueza S; Martín Martínez A; Rodríguez Mendizábal MA; Rosas Gutiérrez L; Martínez López E
An Sist Sanit Navar; 2020 Aug; 43(2):225-234. PubMed ID: 32141442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
